News | August 28, 2012

ICUS Pleased by FDA Modification of Boxed Warnings on Additional Ultrasound Contrast Agents

August 28, 2012 — The International Contrast Ultrasound Society (ICUS) applauded the U.S. Food and Drug Administration’s (FDA) decision to modify the U.S. product label for Optison, an ultrasound contrast agent used to improve the accuracy of radiation-free ultrasound scans. Optison is marketed by GE Healthcare.

The label change was supported by a citizen petition filed by ICUS in October, citing newer scientific studies showing the superior safety profile of ultrasound contrast agents along with their favorable risk-benefit ratios. The citizen petition, which was granted in part by the FDA, also supported a prior modification of the label for Definity, an ultrasound contrast agent marketed by Lantheus Medical Imaging.

The FDA's actions are "an important step forward for patients and for our healthcare system," said Steven Feinstein, a cardiologist at Rush University Medical Center in Chicago and ICUS co-president.

Ultrasound contrast agents are administered intravenously during a noninvasive ultrasound scan to improve image clarity. The procedure does not expose patients to ionizing radiation, and ultrasound contrast agents do not contain dye or increase a patient's risk of nephrotoxicity, according to Feinstein.

"Ultrasound contrast agents are exceedingly safe and completely radiation-free diagnostic imaging tools," he said. "By improving the reliability of a simple front-line ultrasound scan, ultrasound contrast agents also may reduce the need for redundant, expensive and potentially riskier downstream testing — thereby improving patient care while also reducing the overall cost of diagnostic imaging."

The FDA's decision also will spare many patients from the cumulative effects of ionizing radiation that are inherent in certain alternative forms of diagnostic imaging, including SPECT (single photon emission computed tomography) and CT (computed tomography), according to Michael Main, cardiologist and director of the echocardiography laboratory at St. Luke’s Mid-America Heart Institute in Kansas City, Mo., and ICUS treasurer. "The FDA decision should lead to increased use of contrast, better imaging studies, better diagnosis for patients and saved lives," he said.

Main said that although the FDA retained boxed warnings on both ultrasound contrast agents, newer safety data demonstrate a more favorable risk-benefit profile that ultimately may warrant additional label changes with removal of the boxed warnings.

For more information: www.icus-society.org

Related Content

Technology | Focused Ultrasound Therapy | June 19, 2018
EDAP TMS SA has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Focal One device for...
Epsilon Imaging Demonstrates Strain Imaging Integration for Echo Programs at ASE 2018
News | Cardiovascular Ultrasound | June 19, 2018
Clinical practice, along with guidelines and research, have shown that speckle tracking strain imaging can improve...
FDA Clears Bay Labs' EchoMD AutoEF Software for AI Echo Analysis
Technology | Cardiovascular Ultrasound | June 19, 2018
Cardiovascular imaging artificial intelligence (AI) company Bay Labs announced its EchoMD AutoEF software received 510(...
Hitachi Medical Systems Europe Named Imaging Supplier for London Prostate Cancer Program
News | Prostate Cancer | June 14, 2018
Hitachi Medical Systems Europe has been awarded the contract to supply six ultrasound systems as part of the RAPID...
How AI and Deep Learning Will Enable Cancer Diagnosis Via Ultrasound

The red outline shows the manually segmented boundary of a carcinoma, while the deep learning-predicted boundaries are shown in blue, green and cyan. Copyright 2018 Kumar et al. under Creative Commons Attribution License.

News | Ultrasound Imaging | June 12, 2018 | Tony Kontzer
June 12, 2018 — Viksit Kumar didn’t know his mother had...
Olympus and Hitachi Healthcare Americas Introduce Arietta 850
News | Ultrasound Imaging | June 04, 2018
Olympus, a global technology leader in designing and delivering innovative solutions for medical and surgical procedu
New Ultrasound Guidelines Reliably Identify Children Who Should be Biopsied for Thyroid Cancer

Image courtesy of Loyola Medicine

News | Pediatric Imaging | May 29, 2018
A Loyola Medicine study has found that new ultrasound guidelines can reliably identify pediatric patients who should be...
Samsung Receives FDA Clearance for Premium Ultrasound System RS85
Technology | Ultrasound Imaging | May 07, 2018
NeuroLogica, a subsidiary of Samsung Electronics Co. Ltd., announced the Samsung RS85 ultrasound system has received U....
3D-4D ultrasound of a fetus imaged with a GE Volusion E10 system. It shows the yoke sac. This is a baby ultrasound, also referred to as fetal ultrasound or prenatal ultrasound.

3D-4D ultrasound of a fetus imaged with a GE Volusion E10 system. It shows the yoke sac.

Feature | Ultrasound Women's Health | May 07, 2018
Below is a collection of prenatal ultrasound images from the ITN archive.
Esaote Change of Ownership Completed
News | Ultrasound Imaging | April 30, 2018
The acquisition of biomedical equipment company Esaote SpA’s share capital was completed on April 19, the company...
Overlay Init